Related Experiment Video
Updated: Jan 23, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel
Jorge Gómez-Miragaya1, Ander Díaz-Navarro2, Raul Tonda3,4
1Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
Abstract:
Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with de novo and acquired resistance limiting patient's survival. To investigate the genetic basis of docetaxel resistance in TNBC, exome sequencing was performed on matched TNBC patient-derived xenografts (PDX) sensitive to docetaxel and their counterparts that developed resistance in vivo upon continuous drug exposure. Most mutations, small insertions/deletions, and copy number alterations detected in the initial TNBC human metastatic samples were maintained after serial passages in mice and emergence of resistance. We identified a chromosomal amplification of chr12p in a human BRCA1-mutated metastatic sample and the derived chemoresistant PDX, but not in the matched docetaxel-sensitive PDX tumor. Chr12p amplification was validated in a second pair of docetaxel-sensitive/resistant BRCA1-mutated PDXs and after short-term docetaxel treatment in several TNBC/BRCA1-mutated PDXs and cell lines, as well as during metastatic recurrence in a patient with BRCA1-mutated breast cancer who had progressed on docetaxel treatment. Analysis of clinical data indicates an association between chr12p amplification and patients with TNBC/basal-like breast cancer, a BRCA1 mutational signature, and poor survival after chemotherapy. Detection of chr12p amplification in a cohort of TNBC PDX models was associated with an improved response to carboplatin. Our findings reveal tumor clonal dynamics during chemotherapy treatments and suggest that a preexisting population harboring chr12p amplification is associated with the emergence of docetaxel resistance and carboplatin responsiveness in TNBC/BRCA1-mutated tumors. SIGNIFICANCE: Chr12p copy number gains indicate rapid emergence of resistance to docetaxel and increased sensitivity to carboplatin, therefore sequential docetaxel/carboplatin treatment could improve survival in TNBC/BRCA1 patients. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/16/4258/F1.large.jpg.
Insights
Chromosomal amplification of chr12p drives docetaxel resistance in triple-negative breast cancer (TNBC) with BRCA1 mutations. This amplification also predicts better response to carboplatin, suggesting sequential treatment for improved survival.
Area of Science:
- Genomics and Cancer Biology
- Triple-Negative Breast Cancer (TNBC) Research
- Chemotherapy Resistance Mechanisms
Background:
- Taxanes are crucial for triple-negative breast cancer (TNBC) treatment, but resistance limits efficacy.
- Understanding the genetic underpinnings of docetaxel resistance is vital for improving patient outcomes.
- BRCA1-mutated TNBC presents unique challenges in treatment response and resistance.
Purpose of the Study:
- To investigate the genetic basis of docetaxel resistance in TNBC using patient-derived xenografts (PDX).
- To identify specific genetic alterations associated with acquired resistance to docetaxel in TNBC.
- To explore the clinical implications of identified genetic changes for treatment strategies.
Main Methods:
- Exome sequencing of matched docetaxel-sensitive and resistant TNBC PDX models.
- Validation of genetic alterations in PDX models, cell lines, and patient samples.
- Analysis of clinical data correlating genetic findings with treatment response and survival.
Main Results:
- A specific chromosomal amplification of chr12p was identified in docetaxel-resistant TNBC, particularly in BRCA1-mutated tumors.
- Chr12p amplification was associated with acquired resistance to docetaxel and increased sensitivity to carboplatin.
- Clinical data linked chr12p amplification to poor survival after chemotherapy in TNBC patients.
Conclusions:
- Chr12p copy number gains are a significant marker for the rapid emergence of docetaxel resistance in TNBC.
- The findings suggest that chr12p amplification predicts improved response to carboplatin in TNBC/BRCA1-mutated tumors.
- Sequential treatment with docetaxel followed by carboplatin may enhance survival for TNBC patients with BRCA1 mutations.
Related Concept Videos
Treatment Resistant Cancers
Mutations
Viral Mutations
Polytene Chromosomes
Chromosome Structure
The centromere is a DNA sequence that links sister chromatids. This is also where kinetochores, protein complexes to which spindle microtubules attach, are constructed after the chromosome is replicated. The kinetochores allow the spindle microtubules to move the chromosomes within the cell during cell division.
Telomeres consist of non-coding repetitive nucleotide...
Lampbrush Chromosomes
LBCs are made up of two pairs of conjugating homologous chromatids. Each chromatid consists of alternatively positioned regions of condensed-inactive chromatin and loosely placed-active side loops, which can be contracted and extended. The loops...

